CRIS Current Research Information System

TREVISANI, FRANCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.538
AS - Asia 14.466
EU - Europa 10.589
SA - Sud America 862
AF - Africa 784
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 9
Totale 42.278
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.402
VN - Vietnam 4.591
SG - Singapore 3.626
CN - Cina 3.262
GB - Regno Unito 2.508
IT - Italia 1.908
DE - Germania 1.306
SE - Svezia 1.069
HK - Hong Kong 1.019
FR - Francia 753
IN - India 721
BR - Brasile 605
RU - Federazione Russa 568
UA - Ucraina 551
IE - Irlanda 448
NL - Olanda 345
CH - Svizzera 264
JP - Giappone 254
ZA - Sudafrica 242
KR - Corea 232
TG - Togo 228
FI - Finlandia 223
EE - Estonia 194
CI - Costa d'Avorio 122
AR - Argentina 105
JO - Giordania 100
BG - Bulgaria 93
PH - Filippine 89
AT - Austria 75
BD - Bangladesh 75
TH - Thailandia 75
SC - Seychelles 74
ID - Indonesia 69
CA - Canada 66
TR - Turchia 46
PL - Polonia 44
TW - Taiwan 43
BE - Belgio 42
EC - Ecuador 42
ES - Italia 41
PK - Pakistan 39
IQ - Iraq 37
MX - Messico 36
UZ - Uzbekistan 34
IR - Iran 33
CO - Colombia 28
GR - Grecia 28
CL - Cile 27
AU - Australia 24
SA - Arabia Saudita 24
NG - Nigeria 23
HR - Croazia 20
MA - Marocco 20
EG - Egitto 16
VE - Venezuela 16
LT - Lituania 15
MY - Malesia 15
PY - Paraguay 15
CZ - Repubblica Ceca 14
LB - Libano 14
RO - Romania 13
AE - Emirati Arabi Uniti 12
ET - Etiopia 12
HU - Ungheria 12
CR - Costa Rica 10
TN - Tunisia 10
DZ - Algeria 9
PE - Perù 9
DK - Danimarca 8
KZ - Kazakistan 8
LU - Lussemburgo 8
PT - Portogallo 8
BO - Bolivia 7
NP - Nepal 7
OM - Oman 7
SV - El Salvador 7
AZ - Azerbaigian 6
IL - Israele 6
UY - Uruguay 6
EU - Europa 5
JM - Giamaica 5
KE - Kenya 5
MK - Macedonia 5
LV - Lettonia 4
RS - Serbia 4
XK - ???statistics.table.value.countryCode.XK??? 4
AL - Albania 3
BY - Bielorussia 3
CM - Camerun 3
CY - Cipro 3
DO - Repubblica Dominicana 3
GE - Georgia 3
GH - Ghana 3
MD - Moldavia 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
SN - Senegal 3
AO - Angola 2
BH - Bahrain 2
HN - Honduras 2
Totale 42.234
Salva come PNG Salva come JPEG
Città #
Singapore 2.387
Southend 2.169
Fairfield 1.735
Ashburn 1.469
Chandler 1.112
Ho Chi Minh City 1.083
Hanoi 967
Hong Kong 937
San Jose 804
Woodbridge 756
Santa Clara 666
Seattle 661
Houston 653
Wilmington 649
Princeton 558
Cambridge 543
Dong Ket 540
Hefei 463
Bologna 451
Dublin 445
Boardman 394
Ann Arbor 364
Jacksonville 360
Beijing 358
Lauterbourg 297
Los Angeles 269
Bern 238
Westminster 228
Lomé 227
Nanjing 226
Tokyo 218
Padova 199
Seoul 180
Da Nang 168
Helsinki 167
Berlin 162
Dallas 155
Milan 146
Haiphong 137
New York 133
Buffalo 128
Council Bluffs 123
Abidjan 122
Saint Petersburg 105
Shenyang 103
Jinan 100
Amman 99
San Diego 93
Munich 90
Sofia 90
Florence 89
Changsha 86
Frankfurt am Main 82
Medford 79
Redondo Beach 78
Rome 76
Hebei 75
Nanchang 73
Turin 71
São Paulo 70
Guangzhou 68
Mülheim 68
Redmond 67
Dearborn 65
Shanghai 65
Tianjin 61
Hải Dương 57
London 57
Hangzhou 53
Bengaluru 50
Chicago 50
Biên Hòa 49
Des Moines 47
Redwood City 47
Zhengzhou 46
Amsterdam 45
Orem 45
The Dalles 44
Bremen 43
Can Tho 42
Nuremberg 41
Vienna 39
Falls Church 38
Mahé 38
Norwalk 38
Olalla 38
Brussels 36
Ninh Bình 36
Johannesburg 35
Falkenstein 34
Jiaxing 34
Mountain View 32
Bến Tre 30
Phoenix 30
Quận Bình Thạnh 30
Turku 30
Paris 29
Kunming 28
Wuhan 28
Bangkok 27
Totale 27.246
Salva come PNG Salva come JPEG
Nome #
TACE treatment in hepatocellular carcinoma: what should we do now? 343
Efficacy of radioembolization according to tumor morphology and portal vein thrombosis inintermediate-advanced hepatocellular carcinoma 313
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 310
Monofocal hepatocellular carcinoma: How much does size matter? 283
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 280
g-hydroxybutyrate as a treatment for alcoholism. 266
Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. 260
Alcol, sindrome feto-alcolica, apparato ematopoietico, muscolo-scheletrico, respiratorio, cute e reni. 258
Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: A tale of multiple confounders 250
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 249
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 240
A novel sodium overload test predicting ascites decompensation in rats with CCl4-induced cirrhosis. 239
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study 239
Hyperkeratosis of nipple skin during sorafenib treatment 234
Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study 234
Pattern of macrovascular invasion in hepatocellular carcinoma 233
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 231
C-11 Acetate does not enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenoma. 227
Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma 222
Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications 221
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study 220
Prognostication of the outcome of hepatocellular carcinoma: how to rely on science instead of the art of Nostradamus 219
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 218
A novel sodium overload test predicting ascites decompensation in rats with CCL4-induced cirrhosis. 216
Art in hospital: its impact on the feelings and emotional state of patients admitted to an Internal Medicine Unit. 216
BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. 216
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 216
Combined mechanical and pharmacologic thrombolysis for portal vein thrombosis in liver-graft recipients and in candidates for liver transplantation. 215
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 215
Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma 213
The nutritional status modulates preservation-reperfusion injury in rat fatty liver. 212
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatments and outcome. 209
Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma 208
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 207
Oxidative injury in rat fatty liver exposed to ischemia-reperfusion is modulated by nutritional status. 205
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA. database 205
Long-term beta-blockade shortens Qt interval prolongation in patients with liver cirrhosis 203
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 201
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma 201
The changing scenario of hepatocellular carcinoma in Italy: an update 200
Muscle circulation contributes to hyperdynamic circulatory syndrome in advanced cirrhosis. 199
Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20 year multicentre experience. 199
Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients 197
The reduced tolerance of rat fatty liver to ischemia-reperfusion is associated to mitochondrial oxidative injury. 194
Cardiac electrophysiological abnormalities in patients with cirrhosis. 194
Differential diagnosis between focal nodular hyperplasia and hepatocellular adenoma: Potential role of double tracer PET with 11C-Acetate and 18F-FDG 194
Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group 194
Metabolic disorders across hepatocellular carcinoma in Italy 193
Basi scientifiche per la definizione delle linee guida in ambito clinico per l’epatocarcinoma. 191
Recent advances in the natural history of hepatocellular carcinoma. 191
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 189
Daily profile of circulating c-type natriuretic peptide in pre-ascitic cirrhosis and in normal subjects. Relationship with renal function. 188
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice 188
Retrospective analysis of dose–response for HCC lesions treated with 90Y resin microspheres. 187
Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib 186
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 186
C-type natriuretic peptide (CNP) favours natriuresis in pre-ascitic cirrhotic patients. 186
Trattamento farmacologico della intossicazione acuta, sindrome post-sbornia e sindrome d’astinenza da alcol. 185
Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis. 185
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. 184
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. 184
Alfa-fetoprotein in hepatocellular carcinoma (HCC): diagnostic and prognostic role, clinical and biological predictors. Analysis of 1099 patients. 184
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. 183
Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. 182
Insufficienza epatica acuta ed epatite subacuta. 182
Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma 182
Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischemia-reperfusion injury complicated by endotoxemia. 181
Gamma-hydroxybutyric acid plus naltrexone in the treatment of alcoholics resistant to monotherapy. 180
Alcohol misuse and traffic accidents 179
Ablation and resection for hepatocellular carcinoma within Milan criteria and high alpha-foetoprotein levels 178
Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis 178
Immunotherapy with checkpoint inhibitors for hepatocellular carcinoma: Where are we now? 178
Telangiectasia as a presenting sign of Graves’ disease. 176
Suppression of craving for gamma-hydroxybutyric acid by naltrexone administration: three case reports. 175
QT Interval Correction in Patients with Cirrhosis 175
Surveillance for hepatocellular carcinoma in elderly italian patients with cirrhosis. Effects on cancer staging and patients survival. 175
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 175
Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma 174
Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma 173
How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. 173
Terlipressin infusion induces ischemia of breast skin in a cirrothic patient with hepatorenal syndrome 173
Alcolismo 171
QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. 170
Small (≤3cm) Hepatocellular Carcinoma in Cirrhosis: the Role of Double Contrast Agents MR Imaging vs. Multi-Detector Row CT 170
Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 169
Hepatic decompensation is the major driver of death In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. 169
Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. 168
High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing Lamivudine resistance. 168
Storia naturale dell’epatocarcinoma. 168
Torsade de pointes” during amiodarone infusion in cirrhotic woman with the prolonged QT interval. 168
Development and validation of a scoring system that includes corrected QT interval for risk analysis of patients with cirrhosis and gastrointestinal bleeding 168
Serum SCCA-IgM as a predictor of hepatocellular carcinoma in patients with liver cirrhosis 167
Is it time to extend criteria for hepatic resection in the treatment of hepatocellular carcinoma? 167
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study. 166
Adequate Interval For Hepatocellular Carcinoma Surveillance 166
Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study 166
null 164
Retrospective analysis of dose-response for HCC lesions treated with 90Y resin microspheres. 164
Comparison of prognostic models in predicting survival of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: a multicenter cohort study 163
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 163
Totale 20.072
Salva come PNG Salva come JPEG
Categoria #
all - tutte 115.769
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 115.769
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.406 0 0 0 0 0 0 0 0 0 204 164 1.038
2021/20224.643 307 168 267 345 431 244 104 323 197 251 1.273 733
2022/20235.089 511 758 265 597 330 363 178 259 903 125 416 384
2023/20241.571 104 239 113 133 148 283 115 102 111 102 60 61
2024/20255.822 183 904 518 395 1.009 302 385 152 81 428 231 1.234
2025/202614.048 1.425 1.073 1.240 1.040 1.474 840 2.128 691 3.086 1.051 0 0
Totale 42.982